Aspirin and Bleeding-Time: Dependency of Age

Jorgensen, K. Michael; Olesen, Anne Vingaard; Dyerberg, Jørn; Stoffersen, Erik

doi:10.1016/s0140-6736(79)90312-x

Cited by 16 publications

(2 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This potential was used to explain the "aspirin paradox" phenomena, in which aspirin at high doses (3.6 g/day) shortened the bleeding time while at low doses (< 1 g/day) an increase in bleeding time was seen (37,41). However, other authors could not reproduce these results, and found increased bleeding time for both high and low dose regimens (2, 16,24). Amezcua et al…”

Section: Aspirinmentioning

confidence: 93%

Aspirin, a Silent Risk Factor in Urology

Zhu¹,

Davidsen²,

Meyhoff³

1995

Scandinavian Journal of Urology and Nephrology

View full text Add to dashboard Cite

Aspirin is a widely used drug for its analgetic, antiinflamatory and antipyretic effects as well as for prophylactic effect in cardiovascular diseases. However, an increased number of operative hemorrhagic complications in patients on daily aspirin have been reported, an adverse effect highly relevant in urology. In this review the normal hemostatic mechanism and the chief pharmacological effect of aspirin on hemostasis is described. The literature is reviewed for hemorrhagic complications to aspirin in urology. Few reports indicate that aspirin increases bleeding and need for transfusion following prostatectomy, but no placebo-controlled clinical trials with large patient groups have been carried out. Following prostate biopsy and extracorporeal shock wave lithotripsy aspirin-induced hemorrhagic complications have been reported. Cessation of aspirin ingestion one week prior to invasive urologic procedures and correction of bleeding complications with desmopressin, platelet concentration or fresh whole blood is described.

show abstract

Section: Aspirinmentioning

confidence: 93%

Aspirin, a Silent Risk Factor in Urology

Zhu¹,

Davidsen²,

Meyhoff³

1995

Scandinavian Journal of Urology and Nephrology

View full text Add to dashboard Cite

show abstract

“…The variability might be linked to the differences in methodology or to the age of the subjects. Indeed, Jorgensen et al (1979Jorgensen et al ( , 1980 showed that the cutaneous bleeding time in man decreases with age and the response to aspirin varies according to the age, being prolonged in young male volunteers and not in older subject. Moreover, platelet aggregation and TXA2 formation are blocked 2 h after a single dose of aspirin (3.9 g).…”

Section: Ukmentioning

confidence: 99%

Prostacyclin: its biosynthesis, actions and clinical potential

Moncada

Vane

1981

Phil. Trans. R. Soc. Lond. B

View full text Add to dashboard Cite

Prostacyclin (PGI2) is the product of arachidonic acid metabolism generated by the vessel wall of all mammalian species studied, including man. Prostacyclin is a potent vasodilator and the most potent inhibitor of platelet aggregation so far described. Prostacyclin inhibits aggregation through stimulation of platelet adenyl cyclase leading to an increase in platelet cyclic AMP. In the vessel wall, the enzyme that synthesizes prostacyclin is concentrated in the endothelial layer. Prostacyclin can also be a circulating hormone released from the pulmonary circulation. Based on these observations we proposed that platelet aggregability in vivo is controlled via a prostacyclin mechanism. The discovery of prostacyclin has given a new insight into arachidonic acid metabolism and has led to a new hypothesis about mechanisms of haemostasis. Reductions in prostacyclin production in several diseases, including atherosclerosis and diabetes, have been described and implicated in the pathophysiology of these diseases. Additionally, since prostacyclin powerfully inhibits platelet aggregation and promotes their disaggregation, this agent could have an important use in the therapy of conditions in which increased platelet aggregation takes place and in which, perhaps, a prostacyclin deficiency exists. Prostacyclin has been used beneficially in humans during extracorporeal circulation procedures such as cardiopulmonary bypass, charcoal haemoperfusion and haemodialysis. Its possible use in other conditions such as peripheral vascular disease or transplant surgery is at present being investigated.

show abstract

Aspirin-Induced Prolongation of Bleeding Time and Perioperative Blood Loss

Amrein¹

1981

JAMA

View full text Add to dashboard Cite

One hundred twenty-nine patients undergoing total hip replacement were treated with aspirin at a level of either 300 mg four times a day (1.2 g/day) or 900 mg four times a day (3.6 g/day). Baseline bleeding times before aspirin treatment averaged 4.18 +/- 1.44 minutes. Two hours after 300 mg and 900 mg of aspirin, the bleeding times were 5.83 +/- 1.88 and 5.72 +/- 1.57 minutes, respectively. After three to five days of aspirin therapy at 1.2 g/day and 3.6 g/day, the bleeding times were 6.27 +/- 2.27 and 6.43 +/- 2.11 minutes, respectively. The bleeding times for all the aspirin-treated groups were longer than baseline times. No paradoxical shortening of the bleeding time was noted at the 3.6-g/day dose. Perioperative blood loss for those receiving aspirin was not increased in six of eight subsets by operation and anesthesia when compared with historical control subjects. Neither a bleeding time greater than ten minutes nor a prolongation of the bleeding time by aspirin of more than four minutes over baseline bleeding times was associated with increased perioperative blood loss.

show abstract

Aspirin and Bleeding-Time: Dependency of Age

Cited by 16 publications

References 8 publications

Aspirin, a Silent Risk Factor in Urology

Aspirin, a Silent Risk Factor in Urology

Prostacyclin: its biosynthesis, actions and clinical potential

Aspirin-Induced Prolongation of Bleeding Time and Perioperative Blood Loss

Contact Info

Product

Resources

About